Introduction {#s1}
============

CCCs in mammals include the potassium-chloride cotransporters KCC1-4, the sodium-potassium-chloride cotransporters NKCC1-2, the sodium-chloride cotransporter NCC, and CCC8-9 ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}; [@bib3]; [@bib32]; [@bib18]). First characterized as modulators of red blood cell volume ([@bib14]; [@bib29]), CCCs are now appreciated to play critical roles in cellular volume regulation, modulation of neuronal excitability, renal function, auditory system function, transepithelial transport, and blood pressure regulation ([@bib32]; [@bib18]; [@bib49]). CCCs are targets of drugs including the thiazide and loop diuretics hydrochlorothiazide, furosemide, and bumetanide and their disruption is associated with congenital hydrocephaly, epilepsy, hearing loss, Andermann syndrome, Gitelman syndrome, and Bartter syndrome ([@bib18]; [@bib24]; [@bib25]).

KCCs are important for K^+^ and Cl^-^ homeostasis, including in establishing low neuronal cytoplasmic Cl^-^ concentrations critical for inhibitory neurotransmission, and in volume regulation in many cell types ([@bib32]; [@bib6]; [@bib36]; [@bib26]). Among KCCs, KCC4 is most strongly activated by cell swelling and high internal \[Cl^-^\] and is uniquely active in acidic external environments ([@bib32]; [@bib6]). KCC4 is expressed in tissues including the heart, nervous system, kidney, and inner ear and mice lacking KCC4 display progressive deafness and renal tubular acidosis ([@bib32]; [@bib36]; [@bib26]; [@bib9]). Hearing loss in these animals is due to disrupted K^+^ recycling by Dieter's cells in the cochlea and hair cell excitotoxicity, while renal tubular acidosis is due to impaired Cl^-^ recycling by α-intercalated cells in the kidney distal nephron ([@bib9]).

CCCs display varied substrate specificity and transport stoichiometry despite sharing a common amino acid-polyamine-organocation (APC) superfamily fold ([@bib38]; [@bib21]; [@bib47]). KCCs cotransport K^+^:Cl^-^ in a 1:1 ratio, NKCCs cotransport 1K^+^:1Na^+^:2Cl^-^, and NCCs cotransport 1Na^+^:1Cl^-^. One consequence of this difference is that under typical conditions (with \[K^+^\]~in~:\[K^+^\]~out~ \> \[Cl^-^\]~out~:\[Cl^-^\]~in~), transport by KCCs is outwardly directed while transport by NKCCs/NCCs is directed into cells ([@bib32]; [@bib18]).

CCCs have two distinctive elaborations on the APC fold. First, the scaffold is followed by a C-terminal domain (CTD) important for regulating expression, trafficking, and activity including through phosphorylation or dephosphorylation of CTD sites in response to cell swelling ([@bib43]; [@bib7]; [@bib17]; [@bib35]). Second, CCCs contain a 'long extracellular loop' with predicted disulfide bonds and glycosylation sites that differs in position and structure between CCCs; it is formed by the region between TM5-TM6 in KCCs and between TM7-TM8 in NKCCs ([@bib21]; [@bib20]).

KCCs are present as monomers and dimers in cells and modulation of quaternary state has been implicated in transporter regulation. A shift from monomeric to dimeric KCC2 during development coincides with an increase in its activity that results in chloride extrusion from neurons (the excitatory-to-inhibitory GABA switch) ([@bib45]; [@bib8]; [@bib42]). Homodimerization is thought to be largely mediated through CTD interactions, as observed in the recent cryo-EM structure of NKCC1 ([@bib11]), and calpain-mediated proteolysis of the KCC2 CTD is associated with a decrease in transporter activity ([@bib42]). In addition to self-associating, KCCs heterodimerize with other CCCs and interact with other membrane proteins including ion channels ([@bib8]; [@bib48]).

Here we report the structure of *Mus musculus* KCC4 in lipid nanodiscs determined by cryo-EM. The structure reveals unique features of KCCs and, together with functional characterization of structure-based mutants, provides insight into the basis for ion binding, transport, and regulation of KCC4 activity.

Results {#s2}
=======

Structure of KCC4 in lipid nanodiscs {#s2-1}
------------------------------------

*Mus musculus* KCC4 was heterologously expressed in *Spodoptera frugiperda* (Sf9) insect cells for purification and structure determination ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). To assess the activity of KCC4 in these cells, we utilized an assay that depends on the ability of KCCs to transport Tl^+^ in addition to K^+^ ([@bib58]). In cells loaded with the Tl^+^-sensitive fluorophore FluxOR red, Tl^+^ uptake from the extracellular solution results in an increase in fluorescence signal ([Figure 1A](#fig1){ref-type="fig"}). Cells infected with virus encoding KCC4, but not cells infected with a virus encoding an anion-selective volume-regulated ion channel SWELL1 ([@bib27]) or uninfected Sf9 cells, displayed increased fluorescence over time consistent with KCC4 activity ([Figure 1B,C](#fig1){ref-type="fig"}). No significant difference in activity was observed between N- and C-terminally GFP-tagged mouse KCC4 ([Figure 1B,C](#fig1){ref-type="fig"}), in contrast to a previous report for KCC2 ([@bib2]), and C-terminally tagged KCC4 was used for subsequent study.

![Transport activity of mouse KCC4.\
(**A**) Tl^+^ uptake assay for KCC4 activity. KCC4 activity in SF9 cells results in Tl^+^ uptake and increased fluorescence of the Tl^+^ sensitive dye FluxOR Red. (**B**) Fluorescence values as a function of time for each construct assayed. Lines are global exponential fits to all data with 95% confidence intervals shown for KCC4-GFP (n = 8, blue), GFP-KCC4 (n = 3, gray), SWELL1 (n = 3, green), and uninfected SF9 cells (n = 3 red). (**C**) Quantification of experiments shown in (**B**). Normalized final fluorescence. KCC4-GFP 1.0 ± 0.16 (n = 8); GFP-KCC4 0.76 ± 0.33 (n = 3) SWELL1 0.32 ± 0.08 (n = 3) SF9 0.33 ± 0.06 (n = 3); mean ± SEM, one-way Anova (\*p\<0.05, n.s. = not significant).](elife-52505-fig1){#fig1}

We reconstituted KCC4 into lipid nanodiscs in order to study the structure of the transporter in a native-like membrane environment. KCC4 was extracted, purified in detergent, and exchanged into nanodiscs formed by the membrane scaffold protein MSP1D1 and a mixture of phospholipids that approximates the composition of major species in neuronal membranes (2:1:1 molar ratio DOPE:POPC:POPS (2-dioleoyl-sn-glycero-3-phosphoethanolamine:1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine:1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-L-serine)) ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}; [@bib22]; [@bib44]). KCC4-MSP1D1 particles are similar in size and shape to KCC4 particles in detergent micelles by cryo-EM, but show improved distribution in thin ice which enabled reconstruction to high resolution ([Figure 2---figure supplement 3](#fig2s3){ref-type="fig"}).

An unmasked reconstruction of KCC4 in nanodiscs is shown in [Figure 2A](#fig2){ref-type="fig"} contoured to highlight the position of the lipid belt surrounding the transmembrane region. To achieve the highest resolution reconstruction, the nanodisc density was subtracted and particles were subjected to focused classification and subsequent refinement ([Figure 2---figure supplement 4](#fig2s4){ref-type="fig"}). The resulting map, at 3.65 Å overall resolution, enabled complete de novo modeling of the transmembrane and extracellular region of KCC4 and includes two partial extracellular glycosylation sites, a bound K^+^ ion, and a bound Cl^-^ ion ([Figure 2C,D](#fig2){ref-type="fig"}, [Figure 2---figure supplements 5](#fig2s5){ref-type="fig"} and [6](#fig2s6){ref-type="fig"}).

![Structure of mouse KCC4 in lipid nanodiscs.\
(**A**) Cryo-EM map from an unmasked refinement viewed from the membrane plane showing the position of nanodisc, transmembrane region (blue), and extracellular region (green). (**B**) Final map, (**C**) corresponding atomic model, and (**D**) cartoon representation of KCC4. In (**C**), bound K^+^ and Cl^-^ ions are shown as green and violet spheres, respectively. Two disulfides and two N-linked glycosylation sites are shown as sticks and labeled in the cartoon (a third disulfide between TM2 and TM11 is not visible).](elife-52505-fig2){#fig2}

Overall architecture {#s2-2}
--------------------

KCC4 is monomeric in the nanodisc structure. Density for the N-terminal region and C-terminal domain (CTD), which together comprise approximately half the expressed protein mass, is not observed in the cryo-EM maps ([Figure 2](#fig2){ref-type="fig"}). The N-terminal region is weakly conserved, variable in length among CCCs ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}), and is likewise unresolved in the structures of NKCC1 or KCC1 ([@bib11]; [@bib30]). We presume it is highly flexible in KCC4. The C-terminal domain, while similarly unresolved in KCC1 ([@bib30]), is well conserved, has documented roles in regulation, expression, and trafficking ([@bib3]; [@bib32]; [@bib38]; [@bib21]; [@bib43]), and mediates homodimerization of NKCC1 and the Archaean CCC (MaCCC) ([@bib11]; [@bib52]). We found no evidence of proteolytic cleavage of either region. Mass spectrometry of purified KCC4 showed high coverage (47%) and abundance (81% of all KCC4 peptides) for the CTD ([Figure 2---figure supplement 7](#fig2s7){ref-type="fig"}). We observe a progressive loss of detailed features and decrease in local resolution in TM11 and TM12 that connect the CTD to the core transmembrane region ([Figure 2---figure supplements 5B](#fig2s5){ref-type="fig"} and [6](#fig2s6){ref-type="fig"}). Some two-dimensional class averages show a blurred cytoplasmic feature in the position we expect the CTD to emerge ([Figure 2---figure supplement 3B,D](#fig2s3){ref-type="fig"}), but attempts to classify distinct conformations of this feature were unsuccessful. We conclude that the monomeric structure reported here corresponds to full-length mouse KCC4 with flexible and/or disordered terminal regions.

The monomeric structure of KCC4 contrasts with recent homodimeric structures of *Danio rerio* NKCC1 ([@bib11]) and *H. sapiens* KCC1 ([@bib30]), although dimerization of NKCC1 and KCC1 involve completely distinct interfaces ([Figure 3A,C](#fig3){ref-type="fig"}). Disruption of putative tightly associated KCC4 homodimers during purification or sample preparation was excluded for the following reasons: (i) The portion of KCC4 in an early-eluting broad peak from a sizing column ([Figure 2---figure supplement 2A](#fig2s2){ref-type="fig"}) displays nonspecific aggregation by cryo-EM. (ii) KCC4 is monomeric before and after reconstitution in nanodiscs as assessed by cryo-EM ([Figure 2---figure supplements 2](#fig2s2){ref-type="fig"} and [3](#fig2s3){ref-type="fig"}). (iii) Cross-linking of purified KCC4 was observed only at high concentrations of crosslinker and was reduced when KCC4 was first deglycosylated ([Figure 2---figure supplement 2F](#fig2s2){ref-type="fig"}), suggesting some cross-linking in glycosylated KCC4 is from intermolecular glycan-glycan or protein-glycan linkages rather than through transmembrane regions or CTDs ([@bib11]). (iv) No substantial differences were observed in the apparent size of KCC4 or KCC1 (assessed by gel filtration) transporters extracted from different expression host cells or treated with different combinations of detergents used in the CCC structure reports to date ([@bib11]; [@bib30]; [Figure 2---figure supplement 8](#fig2s8){ref-type="fig"}).

![Analysis of putative KCC4 dimerization.\
(**A**) Overlay of monomeric KCC4 (blue) and dimeric KCC1 (protomer one purple, protomer two white, PDB 6KKT) structures viewed from the membrane. (**B**) Magnified top views of the extracellular protein-protein interaction region of KCC1 (dashed box in (**A**)) shown alone with residues in KCC1 labeled (upper) or with KCC4 overlaid (lower) and KCC4 residues labeled. (**C**) Overlay of KCC4 (blue) and dimeric NKCC1 (protomer one orange, protomer two white, PDB 6NPL) structures viewed from the membrane. (**D**) Magnified view of the intracellular protein-protein interaction region of NKCC1 (dashed box in (**C**)). Residues in NKCC1 for which corresponding KCC4 mutations were made are labeled. (**E**) Partial sequence alignments between KCC4 and NKCC1 (above) and human and mouse KCC1 and KCC4 (below) for the regions highlighted in (**B,D**). Residues mutated in KCC4 are numbered in bold. (**F**) Normalized activity of KCC4 mutations. Wild-type KCC4 1 ± 0.11 (n = 11); S404E, R405E, G407E 0.85 ± 0.11 (n = 8); L678R, V680R 0.59 ± 0.10 (n = 8); L670R, A673R 0.64 ± 0.10 (n = 8); S780R, L783R 0.56 ± 0.11 (n = 6); KCC4ΔC (1--658 0.40 ± 0.09 (n = 7); mean ± SEM, one-way Anova (\*p\<0.05, \*\*p\<0.01 \*\*\*p\<0.001).](elife-52505-fig3){#fig3}

We asked whether there are functional consequences of putative KCC4 dimerization through interfaces similar to those observed in KCC1 or NKCC1 structures. The KCC1 dimeric interface is mediated predominantly through protein-detergent interactions between TM regions and protein-protein interactions between an extracellular loop ([@bib30]; [Figure 3A,B](#fig3){ref-type="fig"}). Notably, this loop is poorly conserved in KCCs ([Figure 3E](#fig3){ref-type="fig"}). In KCC4, the loop is incompatible with forming a dimer interface without substantial rearrangement due to steric clashes ([Figure 3B](#fig3){ref-type="fig"}). A triple mutation designed to disrupt interaction between extracellular loops in KCC4 (S404E, R405E, G407E) has no effect on transport activity ([Figure 3B,F](#fig3){ref-type="fig"}). This mutation (and those described later) did not substantially alter KCC4 folding or expression ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). We conclude dimerization as observed in the KCC1 structure ([@bib30]) is not functionally relevant for KCC4.

In NKCC1, dimerization is mediated predominantly through extensive protein-protein interactions in the CTD ([@bib11]). These regions appear well conserved in KCCs ([Figure 3E](#fig3){ref-type="fig"}, [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). Three pairs of mutations designed to disrupt CTD-CTD interactions in KCC4 (L678R, V680R; L670R, A673R; and S780R, L783R) resulted in a similar, but incomplete, reduction in KCC4 activity (by an average of 36, 41, and 44%, respectively) ([Figure 3C,D,F](#fig3){ref-type="fig"}). This reduction is comparable to that observed in a truncated KCC4 construct missing the entire C-terminal region (KCC4ΔC, which includes amino acids 1--658) ([Figure 3F](#fig3){ref-type="fig"}). These results suggest that monomeric KCC4 is active and that dimerization through the CTDs in a manner analogous to NKCC1 increases transport activity.

Transporter conformation {#s2-3}
------------------------

KCC4 adopts an inward-open conformation. The outer surface of the transporter is sealed from the extracellular solution, while a continuous cavity extends from the center of the transmembrane region to the cytoplasmic side ([Figure 4](#fig4){ref-type="fig"}). The transmembrane region consists of twelve helices (TM1-TM12) with TM1-TM5 related to TM6-TM10 through an inverted repeat. TM2 and TM11 in KCC4 are linked by a membrane buried disulfide bond between amino acids C163 (TM2) and C626 (TM11) conserved between KCCs, but not other CCCs ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}).

![Inward-open conformation of KCC4.\
(**A**) Cartoon representation of KCC4 colored with extracellular region green and transmembrane region colored in a gradient from white to blue from N- to C-terminus. Ions and residues forming an extracellular gate are shown as spheres. (**B**) Close-up view of extracellular gate. Residues forming the interaction network are shown as sticks. (**C**) Normalized activity of KCC4 mutations. Wild-type KCC4 1 ± 0.09 (n = 16); K485A 1.15 ± 0.12 (n = 11); K485D 0.25 ± 0.04 (n = 11); K485E 0.44 ± 0.05 (n = 12); F486A 0.52 ± 0.11 (n = 12); E222R 1.19 ± 0.10 (n = 11); R140E 0.30 ± 0.05 (n = 12); N312Q 0.16 ± 0.04 (n = 6); mean ± SEM, one-way Anova (\*\*\*p\<0.001, \*\*\*\*p\<0.0001). (**D**) View of the open pathway to the intracellular ion binding sites. Helices surrounding the ion binding sites are shown as cylinders. Yellow dots demarcate the surface of a bifurcated tunnel that connects the ion binding sites to the cytoplasmic solution. (**E**) Radius of the ion access tunnel as a function of distance along the path for Cl^-^ (pink) and K^+^ (green). (**F**) Electrostatic surface representation of KCC4 sliced to show one leg of the cytoplasmic access tunnel.](elife-52505-fig4){#fig4}

A prominent feature of KCC4 is a large extracellular domain, unique among proteins of known structure, extending \~35 Å above the membrane. It is formed by EL3 (the long extracellular loop; [@bib20]) and EL4, which pack together and cover \~2/3 of the transporter outer surface ([Figures 2C--D](#fig2){ref-type="fig"} and [4A](#fig4){ref-type="fig"}). Sequence comparison suggests it is conserved in all KCCs and not found in other CCCs ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). The structure consists of a short three-stranded antiparallel beta sheet (EL4 S1-3), five short helices (EL3 HA-C and EL4 HA,B), and regions without regular secondary structure. It is stabilized by two disulfide bonds (C308-C323 and C343-C352) ([@bib20]) and decorated with N-linked glycosylation sites ([@bib32]; [@bib55]) conserved among KCCs. Non-protein density consistent with glycosylation is present at four previously identified sites (N312, N331, N344, and N360) ([@bib55]) and we model partial carbohydrate chains at the two stronger sites (N312 and N360). Notably, the carbohydrate chain at N312 projects from the EH3 S1-S2 loop underneath an extended segment that leads to TM6A. This arrangement may stabilize the extracellular domain and couple it to movements in TM6A, which moves between functional states in other APC transporters ([@bib47]; [@bib57]; [@bib28]). Indeed, mutation of this site (N312Q) to prevent glycosylation severely reduces KCC4 activity (by an average of 84%, [Figure 4C](#fig4){ref-type="fig"}). These results provide a structural explanation for functional defects associated with non-glycosylated mutants of KCC4 ([@bib55]).

The position of the extracellular domain suggests its involvement in conformational changes during the KCC transport cycle. A segment of the extracellular domain close to the membrane forms a constriction that seals the internal vestibule from the extracellular solution. This is likely the extracellular gate based on comparison to other APC transporters ([Figure 4A,B](#fig4){ref-type="fig"}; [@bib47]). In KCC4, residues in EL4, TM1, TM3, and TM10 form an electrostatic and hydrophobic interaction network that seals the gate ([Figure 4A,B](#fig4){ref-type="fig"}). R140 on TM1B extends towards the extracellular solution to interact with D575 on TM10 and E222 on TM3. The extracellular domain is positioned immediately above through an interaction between K485 on EL4 and D575. The outer portion of TM1B contributes W143 which, together with F486, surrounds K485 as it projects towards TM10. This is reminiscent of the extracellular gate in LeuT formed by an electrostatic interaction between TM1 and TM10 (R30 and D404) and capped by EL4 through an interaction with TM10 (D401 and A319) ([@bib28]).

We generated mutations at sites in this interaction network to assess its importance for KCC4 function. Disruption of the interaction from the extracellular domain (K485D, K485E, and F486A) or the TM region (R140E) significantly reduced KCC4 transport activity ([Figure 4C](#fig4){ref-type="fig"}). The functional effects of these mutations are likely due to specific disruption of the interaction between the TM region and extracellular domain because a more subtle change (K485A) or mutation of a nearby, but less conformationally restricted, residue (E222R) had no effect on activity ([Figure 4C](#fig4){ref-type="fig"}). By analogy to LeuT and other APC transporters, these data suggest opening of the KCC4 extracellular gate likely requires 'unzipping' of the electrostatic network and rotation of EL4 and the extracellular domain away from the surface of the TM region ([@bib28]; [@bib40]).

On the intracellular side of KCC4, a hydrophilic cavity is formed by TM1, TM3, TM6, and TM8 that exposes the inside of the transporter to the cytoplasm ([Figure 3C--E](#fig3){ref-type="fig"}). At the top of this cavity are Cl^-^ and K^+^ binding sites. The cavity forms a bifurcated pathway for ion access to these sites, splitting into two routes approximately halfway through the tunnel due to the position of side chains of N439, R440, and R528. Both sides are open to an essentially equivalent degree ([Figure 4D](#fig4){ref-type="fig"}). The only constriction outside of the local area surrounding the ions is formed at the position of N439 (from TM6B), G525, and L529 (from TM8) where the cavity narrows to \~3.6 Å in diameter, still sufficiently large for passage of K^+^ and Cl^-^ ions. Within \~3 Å of each ion, the cavity narrows such that it would require at least partial ion dehydration.

The cavity surface is markedly electropositive ([Figure 4E](#fig4){ref-type="fig"}). From the intracellular solution up to the position of the Cl^-^, charged and polar side chains (from R440, R528, R535, N131, N274, N439, and N521), backbone amides (from IL1), and a helical dipole (from TM6B) contribute electropositive character. Since intracellular Cl^-^ ions are typically present at lower concentrations than K^+^ ions, this may serve to favor accumulation of the less abundant substrate near its binding site within transporter. Above the Cl^-^ site and around the K^+^ site, the accessible surface becomes electronegative and would favor cation binding. The extracellular surface of the transporter outside of the sealed gate is markedly electronegative. How this relates to mechanisms for ion binding and release in outward-open states awaits additional structural information.

Ion binding sites {#s2-4}
-----------------

The central discontinuities in TM1 and TM6 result in protein backbone carbonyls and amides not involved in regular hydrogen bonding that are utilized in other APC transporters for substrate binding ([@bib47]). Around this region, we observe two prominent non-protein density features ([Figure 5A,D](#fig5){ref-type="fig"}). Based on structural, functional, and comparative analyses described below, we model these sites as bound K^+^ and Cl^-^ ions.

![Ion binding sites.\
(**A**) K^+^ binding site. The cryo-EM map is shown as blue mesh and KCC4 is colored with carbon yellow, oxygen red, nitrogen blue, and K^+^ green. K^+^-coordination environment is indicated with dashed lines. (**B**) Superposition of K^+^ binding sites in KCC4 (depicted as in (**A**)) and *Danio rerio* NKCC1 (PDB 6NPL) colored with carbons cyan and K^+^ gray. (**C**) Superposition of the Na^+^ (gray) binding site in NKCC1 and analogous region in KCC4. The position of the Na^+^ ion is inferred from SiaT (PDB:5NVA). (**D**) Cl^-^ (pink) binding site and (**E**) superposition of Cl^-^ binding site in KCC4 with analogous lower site in NKCC1. (**F**) Superposition of second upper Cl^-^ binding site in NKCC1 with analogous site in KCC4. (**G**) Normalized activity of KCC4 mutations. Wild-type KCC4 1 ± 0.14 (n = 13); Y216A 0.55 ± 0.08 (n = 13); Y216F 0.22 ± 0.05 (n = 3); Y216H 0.19 ± 0.05 (n = 5); Y589A 0.97 ± 0.12 (n = 5); Y589F 0.35 ± 0.10 (n = 13); Y589H 0.41 ± 0.03 (n = 5); Y466A 0.47 ± 0.05 (n = 5); Y466F 0.98 ± 0.14 (n = 5); Y466H 0.29 ± 0.02 (n = 5); N131A 0.50 ± 0.05 (n = 5); N131D 0.47 ± 0.04 (n = 5); all mean ± SEM, one-way Anova (\*\*p\<0.01, \*\*\*p\<0.001 \*\*\*\*p\<0.0001). (**H**) Model for ion binding and transport stoichiometry in CCC transporters. Helices are shown as cylinders with ion coordination in KCC4 shown as dashed lines to green K^+^ and pink Cl^-^. Helix dipoles in discontinuous helices TM1 and TM6 are indicated. A second upper Cl^-^ site in NKCC1 and KCC1 not observed in the current KCC4 structure is shown as a transparent pink sphere.](elife-52505-fig5){#fig5}

The stronger of the two densities between TM1, TM6, and TM3 is modeled as a K^+^ ion ([Figure 5A](#fig5){ref-type="fig"}). It is surrounded by electronegative groups contributed by backbone carbonyls (N131 and I132 in TM1 and P429 and T432 in TM6) and a tyrosine hydroxyl from Y216 in TM3. The distances between electronegative groups and the ion are consistent with K^+^ binding (2.8--2.9 Å). The electronegative helix dipoles created by TM1A and TM6A may additionally contribute to a favorable electrostatic environment for cation binding. The coordinating tyrosine is conserved in all CCC family members that transport K^+^. In NCC, the position corresponding to Y216 is substituted by a histidine, which likely explains its K^+^-independence ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}).

The second site, between TM6 and TM10, is modeled as a Cl^-^ ion ([Figure 5C](#fig5){ref-type="fig"}). It is surrounded by electropositive groups from backbone amides (G433 and I434 in TM6) and a tyrosine hydroxyl from Y589 in TM10. The electropositive helix dipoles created by TM1B and TM6B may additionally stabilize anion binding. The interaction distances and coordination environment are reminiscent of Cl^-^ sites in CLC transporters ([@bib15]) and the coordinating tyrosine is conserved across CCCs.

To validate the assignment of the K^+^ and Cl^-^ sites and test the importance of coordinating residues in transporter activity, we mutated Y216 and Y589 that contribute to the binding sites to A, F, and H and assessed transporter activity. Mutations at both sites resulted in a marked loss in transport activity in the Tl^+^-flux assay: K^+^-coordinating Y216 mutations Y216A, Y216F, Y216H and Cl^-^-coordinating Y589 mutations Y589F and Y589H reduced activity (by an average of 45, 78, 81, 65% and 59%, respectively) ([Figure 5G](#fig5){ref-type="fig"}). Altering the electrostatic character around the Cl^-^ site with mutations N131A and N131D resulted in comparable transport defects. We conclude the observed K^+^ and Cl^-^ sites are critical for KCC4 activity.

How does substrate binding in the 1:1 K^+^:Cl^-^ cotransporter KCC4 differ from the 1:1:2 Na^+^:K^+^:Cl^-^ cotransporter NKCC1 ([@bib52]; [@bib51])? The KCC4 K^+^ and Cl^-^ sites correspond closely to sites for the same ions in NKCC1 ([Figure 5B,E](#fig5){ref-type="fig"}). However, the proposed Na^+^ site in NKCC1 is dramatically reorganized in KCC4 ([Figure 5C](#fig5){ref-type="fig"}). In KCC4, TM8 is rotated farther away from TM1 and two consecutive Na^+^-coordinating serines in NKCC1 (conserved in all Na^+^-transporting CCCs) are substituted by glycine and alanine in KCC4 (and in KCC1-3) ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). The consequence is a loss of three of the five Na^+^-coordinating positions, providing a structural explanation for Na^+^-independence in KCCs.

A second Cl^-^ site in NKCCs extracellular to the [K^+^]{.smallcaps} site is structurally conserved in KCC4 ([Figure 5F](#fig5){ref-type="fig"}), but we do not observe evidence for ion occupancy at this site in the structure. Interestingly, this site is occupied in a recent structure of KCC1 in addition to the K^+^ and Cl^-^ sites observed in KCC4 ([@bib30]). Mutagenesis of a nearby tyrosine Y466A and Y466H reduce activity of KCC4, suggesting that the integrity of both sites is important for transport ([Figure 5G](#fig5){ref-type="fig"}). Understanding how stoichiometric transport of 1 Cl^-^ with 1 [K^+^]{.smallcaps} in KCC4 is accomplished will require structures in additional functional states.

Discussion {#s3}
==========

Our structural and mutational data are consistent with prior evidence for monomeric KCCs in cells in addition to homodimers and other heterooligomers ([@bib8]; [@bib42]; [@bib54]). Comparison of residues in KCC4 that correspond to those in the KCC1 homodimerization interface ([@bib30]) suggest this interaction is not relevant for KCC4 function. However, comparison to the NKCC1 homodimerization interface ([@bib11]) suggest KCC4 could similarly self-interact and mutational data suggests this interaction increases KCC4 activity. A recently posted report of KCC2 and KCC3 structures appears to show a homodimeric interaction through the CTDs very similar to that observed in NKCC1 ([@bib12]). If monomeric and dimeric KCC4 are functionally distinct, regulated oligomerization in cells would be an opportunity to modulate transport activity. In addition to an increase in basal activity, dimerization involving a close juxtaposition of CTDs and transmembrane regions could enable regulation of transporter activity through CTD posttranslational modifications that may not be possible in monomeric KCC4 with a flexibly attached CTD ([@bib21]; [@bib8]; [@bib42]; [@bib54]). In support of the in vivo relevance of this regulatory mode, a monomeric to dimeric transition in KCC2 has been correlated with an increase in transporter activity ([@bib8]) and is influenced by phosphorylation of the CTD ([@bib54]), while proteolytic cleavage of the KCC2 CTD correlates with a decrease in activity ([@bib42]). The ability of KCC4 to hetero-oligomerize with CCCs and other membrane proteins may be associated with weaker self-interaction compared to other CCCs ([@bib48]; [@bib31]; [@bib19]; [@bib23]).

The structure of KCC4 provides insight into the architecture of KCCs and the mechanistic basis for coupled K^+^:Cl^-^ transport. KCC4 is observed in an inward-open conformation that exposes the inside of the transporter to the cytoplasm through a wide and electropositive tunnel that may serve to concentrate the less abundant intracellular substrate Cl^-^. This conformation is similar to that observed in NKCC1 and KCC1 and presumably represents the lowest energy state for CCCs in symmetrical salt concentrations and the absence of a transmembrane electrical gradient ([@bib11]; [@bib12]). We identify K^+^ and Cl^-^ ions around central discontinuities in TM1 and TM6. A Na^+^ site in the 1:1:2 Na^+^:K^+^:Cl^-^ cotransporter NKCC1 is reorganized in KCC4 due to TM-TM displacement and loss of specific coordinating side chains, explaining Na^+^-independence in KCCs.

Materials and methods {#s4}
=====================

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                         Designation                              Source or reference                                                                                               Identifiers                                                    Additional\
  (species) or resource                                                                                                                                                                                                                                           information
  ------------------------------------- ---------------------------------------- ----------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------- --------------------------------------------------------
  Gene (*Mus musculus*)                 KCC4                                     Synthesized (Thermo Fisher)                                                                                       Uniprot Q80WG5                                                 Codon-optimized for *Spodoptera frugiperda*

  Gene (*Mus musculus*)                 KCC1                                     Synthesized (Thermo Fisher)                                                                                       Uniprot Q9QY75                                                 Codon-optimized for *Spodoptera frugiperda*

  Recombinant DNA reagent               pACEBAC1                                 Geneva Biotech                                                                                                    pACEBac1                                                       Modified as described in Materials and methods

  Cell Line (*Spodoptera frugiperda*)   Sf9                                      Expression Systems                                                                                                Catalog Number: 94--001F                                       

  Cell Line\                            HEK293T                                  ATCC                                                                                                              Catalog Number: CRL-3216                                       
  (*H. sapiens*)                                                                                                                                                                                                                                                  

  Cell Line\                            HEK293T GnTI-                            ATCC                                                                                                              Catalog Number: CRL-3022                                       
  (*H. sapiens*)                                                                                                                                                                                                                                                  

  Peptide, recombinant protein          MSP1D1                                   Prepared as described in doi: [10.1016/S0076-6879(09)64011--8](http://dx.doi.org/10.1016/S0076-6879(09)64011-8)                                                                  His-tag cleaved

  Chemical compound                     DDM                                      Anatrace                                                                                                          Part Number: D310S                                             

  Chemical compound                     CHS                                      Anatrace                                                                                                          Part Number: CH210                                             

  Chemical compound                     Digitonin                                EMD Chemicals                                                                                                     CAS 11024-24-1                                                 

  Chemical compound                     GDN                                      Anatrace                                                                                                          Part Number: GDN101                                            

  Chemical compound                     18:1 (Δ9-Cis) PE (DOPE) lipid            Avanti Polar Lipids                                                                                               SKU: 850725C                                                   

  Chemical compound                     16:0-18:1 PS (POPS) lipid                Avanti Polar Lipids                                                                                               SKU: 840034C                                                   

  Chemical compound                     16:0-18:1 PC (POPC) lipid                Avanti Polar Lipids                                                                                               SKU: 850457C                                                   

  Chemical compound                     FluxOR Red Potassium Ion Channel Assay   ThermoFisher Scientific                                                                                           Catalog Number: F20019                                         

  Software, algorithm                   RELION                                   doi: [10.7554/eLife.42166](http://dx.doi.org/10.7554/eLife.42166)                                                 Relion 3.0.7                                                   

  Software, algorithm                   Cryosparc                                doi: [10.1038/nmeth.4169](http://dx.doi.org/10.1038/nmeth.4169)                                                   Cryosparc2                                                     

  Software, algorithm                   Ctffind                                  doi: [10.1016/j.jsb.2015.08.008](http://dx.doi.org/10.1016/j.jsb.2015.08.008)                                     Ctffind 4.1.13                                                 

  Software, algorithm                   PyEM                                     doi:[10.5281/zenodo.3576630](http://dx.doi.org/10.5281/zenodo.3576630).                                           PyEM                                                           <https://zenodo.org/record/3576630#.XmptWJNKjUI>

  Software, algorithm                   UCSF Chimera                             UCSF                                                                                                              RRID:[SCR_004097](https://scicrunch.org/resolver/SCR_004097)   <http://plato.cgl.ucsf.edu/chimera/>

  Software, algorithm                   COOT                                                                                                                                                       RRID:[SCR_014222](https://scicrunch.org/resolver/SCR_014222)   <http://www2.mrc-lmb.cam.ac.uk/personal/pemsley/coot/>

  Software, algorithm                   Phenix                                                                                                                                                     RRID:[SCR_014224](https://scicrunch.org/resolver/SCR_014224)   <https://www.phenix-online.org/>

  Software, algorithm                   PyMOL                                    PyMOL Molecular Graphics System, Schrodinger LLC                                                                  RRID:[SCR_000305](https://scicrunch.org/resolver/SCR_000305)   <https://www.pymol.org/>
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Cloning and protein expression {#s4-1}
------------------------------

Cloning, expression, and purification were performed similarly to that described for LRRC8A ([@bib27]). The sequence for KCC4 and KCC1 from *Mus musculus* were codon optimized for *Spodoptera frugiperda* and synthesized (Thermo Fisher, Cambridge, MA). Sequences were cloned into a custom vector based on the pACEBAC1 backbone (MultiBac; Geneva Biotech, Geneva, Switzerland) with an added C-terminal PreScission protease (PPX) cleavage site, linker sequence, superfolder GFP (sfGFP), and 7xHis tag, generating a construct for expression of mmKCC4-SNS-LEVLFQGP-SRGGSGAAAGSGSGS-sfGFP-GSS-7xHis. Mutations were introduced using standard PCR techniques with partially overlapping primers. MultiBac cells were used to generate bacmids according to manufacturer's instructions. *Spodoptera frugiperda* (Sf9) cells were cultured in ESF 921 medium (Expression Systems, Davis, CA) and P1 virus was generated from cells transfected with Escort IV Transfection Reagent (Sigma, Carlsbad, CA) according to manufacturer's instructions. P2 virus was generated by infecting cells at 2 × 10^6^ cells/mL with P1 virus at a MOI \~ 0.1. Infection monitored by fluorescence of sfGFP-tagged protein and P2 virus was harvested at 72 hr post infection. P3 virus was generated in a similar manner to expand the viral stock. The P3 viral stock was then used to infect 1 L of Sf9 cells at 4 × 10^6^ cells/mL at a MOI \~ 2--5. At 60 hr post-infection, cells were harvested by centrifugation at 2500 x g and frozen at −80°C.

Transporter assay {#s4-2}
-----------------

The FluxOR-Red Potassium Ion Channel Assay (Thermo Fisher Scientific) was adapted for transport assays in Sf9 insect cells by adjusting the osmolarity of all buffers to 380 mOsm (by addition of sodium methylsulfonate). Cells were infected at a density of 1.5 × 10^6^ cells/ml and grown in suspension for 60--72 hr for robust KCC4-GFP expression. 100 uL of cells at 1 × 10^6^ cells/ml were plated and allowed to adhere for 1 hr before the assay. For experiments in [Figures 3](#fig3){ref-type="fig"}--[5](#fig5){ref-type="fig"}, 100 uL of cells at 1 × 10^6^ cells/ml were plated and allowed to adhere for 1 hr before viral infection. Cells were grown for 60--72 hr for robust transporter expression prior to assay. Growth media was replaced with 1X Loading Buffer and incubated at 27°C away from light for 1 hr. The FluxOR Red reagent is a non-fluorescent indicator dye which is loaded into cells as a membrane-permeable acetoxymethyl (AM)-ester. The non-fluorescent AM ester of the FluxOR Red reagent is cleaved by endogenous esterases into a fluorogenic Tl^+^-sensitive indicator. 1X Loading Buffer was subsequently removed and replaced with Dye-free Assay Buffer and FluxOR Background Suppressor. The assay was performed in 96-well, black-walled, clear-bottom plates (Costar). For data in [Figure 1](#fig1){ref-type="fig"}, fluorescence was measured on a Perkin-Elmer Envision Multilabel Plate Reader using bottom read fluorescence and a BODIPY TMR FP filter set (excitation 531 nm and 25 nm bandwidth, emission 595 nm and 60 nm bandwidth). For data in [Figures 3](#fig3){ref-type="fig"}--[5](#fig5){ref-type="fig"}, Fluorescence was measured on a Molecular Devices SpectraMax M3 using bottom read fluorescence and an excitation 560 nm with auto cutoff at 590 nm and emission 590 nm. The recordings were baseline corrected by subtracting the average fluorescence from 180 s prior to the addition of Basal Potassium Stimulus buffer and time zero is defined as the first data point recorded after the addition of stimulus. Global fits of all data to a one phase association model Y=(Plateau)\*(1-e^(-x/𝜏)^) are displayed with 95% confidence interval bands ([Figure 1B](#fig1){ref-type="fig"}). Alternatively, the final 50 counts were averaged as a measure of final fluorescence increase and normalized to wild-type KCC4 fluorescence increase from experiments performed on the same day. In some experiments, average GFP fluorescence was measured between FluxOR fluorescence measurements and used to normalize FluxOR fluorescence values to account for differences in expression level. This normalization did not change results in a significant way and so was not performed for the final data presented.

Protein purification {#s4-3}
--------------------

Cells from 1 L of culture (\~7--12.5 mL of cell pellet) were thawed in 100 mL of Lysis Buffer (50 mM Tris, 150 mM KCl, 1 mM EDTA, pH 8.0). Protease inhibitors were added to the lysis buffer immediately before use (final concentrations: E64 (1 µM), Pepstatin A (1 µg/mL), Soy Trypsin Inhibitor (10 µg/mL), Benzimidine (1 mM), Aprotinin (1 µg/mL), Leupeptin (1 µg/mL), and PMSF (1 mM)). Benzonase (5 µl) was added after cells thawed. Cells were then lysed by sonication and centrifuged at 150,000 x g for 45 min. The supernatant was discarded, and residual nucleic acid was removed from the top of the membrane pellet by rinsing with DPBS. A 10%/2% and 10%/1% w/v solution of DDM/CHS was clarified by bath sonication in 200 mM Tris pH 8.0 and subsequently added to buffers at the indicated final concentrations. Membrane pellets were transferred to a glass dounce homogenizer containing Extraction Buffer (50 mM Tris, 150 mM KCl, 1 mM EDTA, 1% w/v n-Dodecyl-β-D-Maltopyranoside (DDM, Anatrace, Maumee, OH), 0.2% w/v Cholesterol Hemisuccinate Tris Salt (CHS, Anatrace), pH 8.0). Membrane pellets were homogenized in Extraction Buffer and this mixture (100 mL final volume) was gently stirred at 4°C for 1 hr. The extraction mixture was centrifuged at 33,000 x g for 45 min. The supernatant, containing solubilized KCC4-sfGFP, was bound to 5 mL of Sepharose resin coupled to anti-GFP nanobody for 1 hr at 4°C. The resin was collected in a column and washed with 20 mL of Buffer 1 (20 mM Tris, 150 mM KCl, 1 mM EDTA, 0.025% DDM, 0.005% CHS, pH 8.0), 50 mL of Buffer 2 (20 mM Tris, 500 mM KCl, 1 mM EDTA, 0.025% DDM, 0.005% CHS, pH 8.0), and 20 mL of Buffer 1. Washed resin was resuspended in 6 mL of Buffer 1 with 0.5 mg of PPX and rocked gently in the capped column overnight. Cleaved KCC4 protein was eluted with an additional 25 mL of Buffer 1. The eluted pool was concentrated to \~500 µl with an Amicon Ultra spin concentrator 100 kDa cutoff (MilliporeSigma, USA) and subjected to size exclusion chromatography using a Superose 6 Increase column (GE Healthcare, Chicago, IL) run in Buffer 3 (20 mM Tris pH 8.0, 150 mM KCl, 1 mM EDTA, 0.025% DDM, 0.0025% CHS) on a NGC system (Bio-Rad, Hercules, CA). Peak fractions containing KCC4 transporter were collected and concentrated.

Fluorescence Size Exclusion Chromatography (FSEC) {#s4-4}
-------------------------------------------------

Sf9 cells were plated at 1 × 10^6^ cells/ml into six well plates and allowed to adhere for 1 hr prior to viral infection at a ratio of 1:30 (v/v). Cells were harvested after 60--72 hr, pelleted by centrifugation, and frozen. Transfected HEK 293T GNTI- cells were prepared using Lipofectamine 2000 according to manufacturer's instructions. Media was switched 18 hr post-transfection to fresh media with 10 mM sodium butyrate. Cells were incubated for 19 hr longer at 30°C, harvested, pelleted by centrifugation, and frozen.

Frozen samples containing \~8 million infected Sf9 cells and \~1 million transfected HEK 293T GNTI- cells were thawed, extracted for 1 hr at 4°C, and pelleted at 21,000 x g at 4°C for 1 hr. Supernatant was run on a Superose 6 Increase column with fluorescence detection for GFP. For mutant comparisons ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}), extraction buffer was (50 mM Tris pH 8, 150 mM KCl, 1 mM EDTA, all protease inhibitors used for protein purification, 1% DDM, 0.2% CHS) and running buffer was (20 mM Tris pH8, 150 mM KCl, 1 mM EDTA, 0.025% DDM, 0.0025% CHS). The same buffers were used for the 'DDM/CHS' conditions in [Figure 2---figure supplement 8A,B,C](#fig2s8){ref-type="fig"} and in [Figure 2---figure supplement 8D,E](#fig2s8){ref-type="fig"} except that running buffer in [Figure 2---figure supplement 8E](#fig2s8){ref-type="fig"} contained (0.025% DDM, 0.005% CHS). The 'GDN' condition used in [Figure 2---figure supplement 8A,B,C](#fig2s8){ref-type="fig"} corresponds to conditions used for KCC1 structure determination ([@bib30]). Extraction buffer was (20 mM Tris pH8, 150 mM KCl, all protease inhibitors used for protein purification, 2% DDM, 0.2% CHS). Running buffer was (20 mM Tris pH8, 150 mM KCl, 0.06% GDN). The 'Digitonin' condition used in [Figure 2---figure supplement 8A,B,C](#fig2s8){ref-type="fig"} corresponds to conditions used for NKCC1 structure determination ([@bib11]). Extraction buffer was (50 mM Tris pH 8, 150 mM KCl, 1 mM EDTA, all protease inhibitors used for protein purification, 1% LMNG, 0.01% CHS) and running buffer was (20 mM Tris pH8, 150 mM KCl, 1 mM EDTA, 0.06% Digitonin).

Cross linking and mass spectrometry {#s4-5}
-----------------------------------

Fractions corresponding to peaks 1 and 2 from size exclusion chromatography were separately pooled and concentrated to 0.5 mg/mL. Crosslinking was performed by adding 1 uL of glutaraldehyde from 10X stock solutions in water to 10 uL of KCC4 to achieve final glutaraldehyde concentrations of 0.02, 0.01, 0.005, 0.0025, and 0%. Samples were incubated for 30 min prior to quenching by addition of 1 uL 1M Tris-HCl and analysis by SDS-PAGE on 4--12% Tris-glycine gel (BioRad, USA). Deglycosylated samples were pretreated with 1:10 vol purified PNGase at 1 mg/mL (Addgene 114274) for 1 hr at 4°C prior to the addition of glutaraldehyde.

For mass spectrometry, the band corresponding to purified KCC4 was excised from a 4--12% Tris-glycine gel, digested with trypsin in situ, and the resulting peptides extracted and concentrated. Mass spectrometry was performed by the Vincent J. Coates Proteomics/Mass Spectrometry Laboratory at UC Berkeley. A nano LC column was packed in a 100 μm inner diameter glass capillary with an emitter tip. The column consisted of 10 cm of Polaris c18 5 μm packing material (Varian), followed by 4 cm of Partisphere 5 SCX (Whatman). The column was loaded by use of a pressure bomb and washed extensively with buffer A (5% acetonitrile/0.02% heptaflurobutyric acid (HBFA)). The column was then directly coupled to an electrospray ionization source mounted on a Thermo-Fisher LTQ XL linear ion trap mass spectrometer. An Agilent 1200 HPLC equipped with a split line so as to deliver a flow rate of 300 nl/min was used for chromatography. Peptides were eluted using a 4-step MudPIT procedure ([@bib53]). Buffer A was 5% acetonitrile/0.02% heptaflurobutyric acid (HBFA); buffer B was 80% acetonitrile/0.02% HBFA. Buffer C was 250 mM ammonium acetate/5% acetonitrile/0.02% HBFA; buffer D was same as buffer C, but with 500 mM ammonium acetate.

Protein identification was done with Integrated Proteomics Pipeline (IP2, Integrated Proteomics Applications, Inc San Diego, CA) using ProLuCID/Sequest, DTASelect2 and Census ([@bib56]; [@bib50]; [@bib37]). Tandem mass spectra were extracted into ms1 and ms2 files from raw files using RawExtractor ([@bib34]). Data was searched against a *Spodoptera frugiperda* protein database with the purified mouse KCC4 sequence added, supplemented with sequences of common contaminants, and concatenated to form a decoy database ([@bib39]). LTQ data was searched with 3000.0 milli-amu precursor tolerance and the fragment ions were restricted to a 600.0 ppm tolerance. All searches were parallelized and searched on the VJC proteomics cluster. Search space included all half tryptic peptide candidates with no missed cleavage restrictions. Carbamidomethylation (+57.02146) of cysteine was considered a static modification. In order to identify authentic termini, we required one tryptic terminus for each peptide identification. The ProLuCID search results were assembled and filtered using the DTASelect program with a peptide false discovery rate (FDR) of 0.001 for single peptides and a peptide FDR of 0.005 for additional peptides for the same protein. Under such filtering conditions, the estimated false discovery rate was less than 1%.

Nanodisc reconstitution {#s4-6}
-----------------------

Freshly purified and concentrated KCC4 in Buffer three was reconstituted into MSP1D1 nanodiscs with a mixture of lipids (DOPE:POPS:POPC at 2:1:1 molar ratio, Avanti, Alabaster, Alabama) at a final molar ratio of KCC4:MSP1D1:lipids of 0.2:1:50. Lipids in chloroform were prepared by mixing, drying under argon, washing with pentane, drying under argon, and placing under vacuum overnight. The dried lipid mixture was rehydrated in Buffer 4 (20 mM Tris, 150 mM KCl, 1 mM EDTA pH 8.0) and clarified by bath sonication. DDM was added to a final concentration of 8 mM and the detergent solubilized lipids were sonicated until clear. Lipids, Buffer 4 containing 8 mM DDM, and KCC4 protein were mixed and incubated at 4°C for 30 min before addition of purified MSP1D1. After addition of MSP1D1, the nanodisc formation solution was 47.5 µM KCC4, 104 µM MSP1D1, 13 mM DOPE:POPS:POPC, and 4 mM DDM in Buffer 4 (final concentrations). After mixing at 4°C for 30 mins, 60 mg of Biobeads SM2 (Bio-Rad, USA) (prepared by sequential washing in methanol, water, and Buffer four and weighed damp following bulk liquid removal) were added and the mixture was rotated at 4°C overnight (\~12 hr). Nanodisc-containing supernatant was collected and spun for 10 min at 21,000 x g before loading onto a Superose 6 Increase column in Buffer 4. Peak fractions corresponding to KCC4-MSP1D1 were collected and spin concentrated using a 100 kDa cutoff for grid preparation.

Grid preparation {#s4-7}
----------------

The KCC4-MSP1D1 nanodisc sample was concentrated to \~1 mg/mL and centrifuged at 21,000 x g for 10 min at 4°C prior to grid preparation. A 3 uL drop of protein was applied to a freshly glow discharged Holey Carbon, 400 mesh R 1.2/1.3 gold grid (Quantifoil, Großlöbichau, Germany). A Vitrobot Mark IV (FEI/Thermo Scientific, USA) was utilized for plunge freezing in liquid ethane with the following settings: 4°C, 100% humidity, one blot force, 3 s blot time, 5 s wait time. The KCC4 detergent sample was frozen at 4.5 mg/mL and centrifuged at 21,000 x g for 10 min at 4°C prior to grid preparation. A 3 µL drop of protein was applied to a freshly glow discharged Holey Carbon, 400 mesh R 1.2/1.3 gold grid. A Vitrobot Mark IV (FEI/Thermo Scientific, USA) was utilized for plunge freezing in liquid ethane with the following settings: 4°C, 100% humidity, one blot force, 4 s blot time, 1 s wait time. Grids were clipped in autoloader cartridges for data collection.

Data collection {#s4-8}
---------------

KCC4-MSP1D1 grids were transferred to a Talos Arctica cryo-electron microscope (FEI/Thermo Scientific, USA) operated at an acceleration voltage of 200 kV. Images were recorded in an automated fashion with SerialEM ([@bib33]) using image shift with a target defocus range of −0.7 \~ −2.2 µm over 5 s as 50 subframes with a K3 direct electron detector (Gatan, USA) in super-resolution mode with a super-resolution pixel size of 0.5685 Å. The electron dose was 9.333 e^-^ / Å ([@bib32])/s (0.9333 e^-^/ Å2/frame) at the detector level and total accumulated dose was 46.665 e-/Å2. KCC4-detergent grids were transferred to a Titan Krios cryo-electron microscope (FEI/Thermo Scientific, USA) operated at an acceleration voltage of 300 kV. Images were recorded in an automated fashion with SerialEM ([@bib33]) with a target defocus range of −0.7 to −2.2 µm over 9.6 s as 48 subframes with a K2 direct electron detector (Gatan, USA) in super-resolution mode with a super-resolution pixel size of 0.5746 Å. The electron dose was 6.092 e^-^ / Å ([@bib32])/s (1.2184 e^-^ / Å ([@bib32])/frame) at the detector level and total accumulated dose was 58.4832 e^-^/Å ([@bib32]). See also [Table 1](#table1){ref-type="table"} for data collection statistics.

###### Cryo-EM data collection and structure refinement statistics.

  -------------------------------------------- --------------
  Data collection                              
  Total movie \#                               1572
  Selected movie \#                            1401
  Magnification                                36,000x
  Voltage (kV)                                 200
  Electron exposure (e^--^/Å^2^)               46.665
  Frame \#                                     50
  Defocus range (μm)                           −0.7 to −2.5
  Super resolution pixel size (Å)              0.5685
  Binned pixel size (Å)                        1.137
  Processing                                   
  Initial particle images (no.)                887,132
  Final particle images (no.)                  110,143
  Map resolution                               
  Masked (Å, FSC = 0.143/ FSC=0.5)             3.6/4.2
  Unmasked (Å, FSC = 0.143/ FSC=0.5)           3.9/4.4
  Refinement                                   
  Model resolution (Å, FSC = 0.143/ FSC=0.5)   3.5/3.9
  Map-sharpening *B *factor (Å^2^)             −150
  Composition                                  
  Number of atoms                              4103
  Number of protein residues                   536
  Ligands total                                4
  K+                                           1
  Cl-                                          1
  NAG-NAG-BMA                                  2
  R.m.s. deviations                            
  Bond lengths (Å)                             0.005
  Bond angles (°)                              0.731
  Validation                                   
  MolProbity score                             1.7
  Clashscore                                   4.59
  EMRinger score                               1.74
  Ramachandran plot                            
  Favored (%)                                  92.48
  Allowed (%)                                  7.52
  Disallowed (%)                               0
  Rotamer outliers (%)                         0.23
  Mean *B* factors (Å^2^)                      
  Protein                                      75.41
  Ligand                                       106.62
  -------------------------------------------- --------------

Data processing {#s4-9}
---------------

The processing pipeline is shown in [Figure 2---figure supplement 4A--C](#fig2s4){ref-type="fig"}. We used Cryosparc2 ([@bib41]) for initial model generation and refinement until reconstructions reached 4--5 Å resolution. Bayesian polishing and nanodisc subtraction in Relion 3.0.7 ([@bib61]; [@bib60]) were used to achieve highest resolution reconstructions. While the contribution of disordered or flexible N- and C-terminal regions to alignments is unknown, the remaining 55 kDa asymmetric membrane protein is among the smallest in terms of resolved mass resolved by cryo-EM to date.

A total of 1572 movie stacks were collected, motion-corrected and binned to 1.137 Å/pixel using MotionCor2 ([@bib59]), and CTF-corrected using Ctffind 4.1.13 ([@bib46]; [Figure 2---figure supplement 4A](#fig2s4){ref-type="fig"}). Micrographs with a Ctffind reported resolution estimate worse than 5 Å were discarded. A small number of particles (\~1000) were picked manually and subjected to two-dimensional classification to generate references for autopicking in Relion. 1,826,000 particles were autopicked and extracted at 2.274 Å/pixel (2x binned) for initial cleanup. Non-particle picks and apparent junk particles were removed by several rounds of two-dimensional class averaging. The remaining 887,132 particles were extracted at 1.137 Å/pixel and imported into Cryosparc. An additional round of 2D classification generated a particle set of 491,111. These particles were the input of an ab initio reconstruction (non-default values: four classes, 0.1 class similarity, 4 Å max resolution, per-image optimal scales). 2D classification of particles (160,868) that contributed to the most featured volume resulted in a set of 125,593 particles which were the input of an ab initio reconstruction. Alignments were iteratively improved using non-uniform (NU) refinement (0.89 window inner radius, 120 voxel box size, 10 extra final passes, 10 Å low-pass filter, 0.01 batch epsilon, minimize over per-particle scale, 1--4 Å dynamic mask near, 3--8 Å dynamic mask far, 6--10 Å dynamic mask start resolution, 4--6 Å local processing start resolution). Two separate NU refinement output volumes were input into a heterogeneous refinement job of the 886,528 particle set (forced hard classification, 10 Å initial resolution, five final full iterations). The more featured class (538,280 particles) was heterogeneously refined (forced hard classification, 10 Å initial resolution, five final full iterations) ([Figure 2---figure supplement 4B](#fig2s4){ref-type="fig"}). The particles and volume from one output (354,234 particles) were input into the first of three iterative NU refinements (10 extra final passes for the second and third iteration).

Particle positions and angles from the final cryoSPARC2 refinement job were input into Relion (using csparc2relion.py from the UCSF PyEM \[[@bib4]\]) and 3D refined to generate a 4.18 Å map (6 Å low-pass filter, 0.9 degrees initial sampling, 0.9 degrees local searches) ([Figure 2---figure supplement 4C](#fig2s4){ref-type="fig"}). A second 3D refinement following Bayesian particle polishing improved the map and reported resolution (4.01 Å) (6 Å low-pass filter, 0.9 degrees initial sampling, 0.9 degrees local searches). CTF refinement with beam tilt group estimation and per-particle defocus was performed, although subsequent 3D refinement did not markedly improve the map. Particle subtraction was performed to remove the contribution of the nanodisc density from alignments and subsequent 3D refinement markedly improved the map (reported resolution 3.86 Å or 3.72 Å after postprocessing) (6 Å low-pass filter, 0.9 degrees initial sampling, 0.9 degrees local searches). A final improvement in map quality and reported resolution and was obtained by removing poor particles with a 3D classification job (two classes, 10 Å initial low-pass filter, 16 tau fudge, no angular sampling). The final particle set (110,143) was subjected to 3D refinement to generate a final map at 3.72 Å resolution (3.65 Å after postprocessing) (6 Å low-pass filter, 0.9 degrees initial sampling, 0.9 degrees local searches). Particle distribution and local resolution was calculated using Relion ([Figure 2---figure supplement 5A,B](#fig2s5){ref-type="fig"}). FSCs reported in [Figure 2---figure supplement 5](#fig2s5){ref-type="fig"} were calculated using Phenix.mtriage.

Modeling, refinement, and structure analysis {#s4-10}
--------------------------------------------

The final cryo-EM maps were sharpened using Phenix.autosharpen ([@bib1]). The structure was modeled de novo in Coot and refined in real space using Phenix.real_space_refine with Ramachandran and NCS restraints. Validation tools in Phenix, EMRinger ([@bib5]), and Molprobity ([@bib10]) were used to guide iterative rounds of model adjustment in Coot and refinement in Phenix. Cavity measurements were made with HOLE implemented in Coot ([@bib16]). Electrostatic potential was calculated using APBS-PDB2PQR ([@bib13]) Pymol plugin. Figures were prepared using PyMOL, Chimera, ChimeraX, Fiji, Prism, Adobe Photoshop, and Adobe Illustrator software.
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The final map of KCC4 in MSP1D1 nanodiscs has been deposited to the Electron Microscopy Data Bank under accession code EMD-20807. Atomic coordinates have been deposited in the PDB under ID 6UKN. Original KCC4 in MSP1D1 nanodiscs micrograph movies have been deposited to EMPIAR under deposition EMPIAR-10394.

The following datasets were generated:

ReidMSKernDMBrohawnSG2020Cryo-EM structure of the potassium-chloride cotransporter KCC4 in lipid nanodiscsElectron Microscopy Public Image Archive10394

ReidMSKernDMBrohawnSG2019Cryo-EM structure of the potassium-chloride cotransporter KCC4 in lipid nanodiscsElectron Microscopy Data BankEMD-20807

ReidMSKernDMBrohawnSG2019Cryo-EM structure of the potassium-chloride cotransporter KCC4 in lipid nanodiscsRCSB Protein Data Bank6UKN

10.7554/eLife.52505.sa1

Decision letter

Kühlbrandt

Werner

Reviewing Editor

Max Planck Institute of Biophysics

Germany

Chen

Jue

Reviewer

The Rockefeller University

United States

Padan

Etana

Reviewer

Hebrew University

Israel

In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Acceptance summary:**

The CCC family of sodium-potassium-chloride cotransporters belong to the SLC12 family of solute carriers, which play a fundamental role in regulating cellular ion homeostasis. Here, Reid et al. report the cryo-EM structure of KCC4, a member of the electroneutral potassium-chloride cotransporter subfamily, from *Mus musculus* in lipid nanodiscs. The structural data reveal differences in the ion-binding sites between KCC and NKCC members, explaining differences in stoichiometry and ion preferences in the larger SLC12 family. Analysis of the extracellular domain in KCC4 builds on previous structures from KCC1, and highlights an intriguing role for glycosylation in regulating transport function. Functional studies demonstrated that KCC4 could function as both monomer and dimer in the cell, with dimerization increasing activity and possibly linked to activation during cell swelling.

**Decision letter after peer review:**

\[Editors' note: the authors submitted for reconsideration following the decision after peer review. What follows is the decision letter after the first round of review.\]

Thank you for submitting your work entitled \"Cryo-EM structure of the potassium-chloride cotransporter KCC4 in lipid nanodiscs\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and a Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Jue Chen (Reviewer \#1) and Etana Padan (Reviewer \#3).

Our decision has been reached after consultation between the reviewers. Based on these discussions and the individual reviews below, we regret to inform you that we cannot consider your work for publication in *eLife* at this stage. We would be happy to consider a resubmission, if you revise your manuscript along the lines suggested below.

Summary:

The manuscript by Reid et al. reports the structure of the mammalian potassium chloride cotransporter KCC4, determined by single-particle cryo-EM in lipid nanodiscs. KCC4 is member of the larger Cation Chloride Cotransporter superfamily, which plays essential roles in regulating ion homeostasis in the cell. The structure comes hot on the heels of other CCC family members, NKCC1 and KCC1, which makes it potentially a valuable addition to the study of these physiologically important antiporters. As it stands, the manuscript does however not present a sufficient advance over recently published work.

Our main concerns were as follows:

1\) While all reviewers find the paper interesting and potentially important, they are concerned that this is the third structure of this family of transporters. The other two, which were published earlier this year, are human KCC1 and DrNKCC1. In your structure, the transmembrane domain is nearly identical to the other two, including the ion binding sites. The major difference is that KCC4 is a monomer and the others are dimers. This would be an opportunity to understand dimerization as a new aspect of these transporters. Unfortunately this difference is only addressed superficially in the discussion but without data or analysis. If you can provide evidence that the monomeric form of KCC4 is active, for example by ITC, it would be a valuable addition. If you could show that the ion transport or ion binding kinetics for the monomer and dimer are different, this would add considerable weight to your study.

2\) A related concern was that your study provides little in the way of insight into the regulation of the protein. While you propose that monomer-dimer transitions may occur during regulation of the protein in cells, no evidence is provided that this is actually the case.

3\) The fact that KCC4 is a monomer is surprising, given that the KCC1 structure, which is closely related, was determined as a dimer using a similar technique. Could the use of 1% DDM be responsible for disrupting the dimer during isolation? Native mass spectrometry might be a good way of analyzing this important aspect of KCC structure and regulation.

4\) A further point that would benefit from additional analysis is the role of the extracellular domain. You describe this domain as novel, but without investigating its function, either in cells or in vitro. You describe glycosylation, including what appears to be an interesting link between glycosylation at N312 and TM6A, which forms part of the transport machinery in APC proteins. Yet, the significance of this interaction is not clear. Is it an artifact or an important part of the mechanism?

5\) We also wondered about the extracellular gate, where you describe a salt bridge network that may function in a similar way to LeuT (and other APC transporters), but no analysis is provided. It would be good to characterize these interactions, for example through transport assays with variants at these sites and charge-swapped mutants. Such experiments would illuminate the mechanism of KCC4 and help to put the structure into a functional context.

Reviewer \#1:

This paper describes the cryo-EM structure of KCC4, a K^+^/Cl^-^ cotransporter from *Mus musculus*. The structural work is well done, two residues in the ion-binding sites were mutated to demonstrate their importance to transport activity.

My main concern is this:

This is the third structure of this family of transporters. The other two, which were published earlier this year, are human KCC1 and DrNKCC1. The new structure in detail is nearly identical to the previous ones, including the ion binding sites. Some of the figures here are also similar. The major difference is that KCC4 is a monomer and the others are dimers. This is an opportunity to understand an aspect of these transporters that until now was unknown. Unfortunately this difference is only addressed superficially in discussion but not with data and analysis. If the authors can provide evidence that the monomeric form of KCC4 is functional, then this work will make a good contribution towards our understanding of the architecture and function of KCCs.

Reviewer \#2:

The study by Reid et al. reports the structure of the mammalian potassium chloride cotransporter KCC4, determined using single particle Cryo-EM in lipid nanodiscs. KCC4 is member of the larger Cation Chloride Cotransporter superfamily, members of which play essential roles in regulating ion homeostasis in the cell. This structure comes hot on the heels of other CCC family members, NKCC1 and KCC1, which makes the current structure a valuable addition to the literature on these physiologically important antiporters. The structure appears to be of good quality and is accompanied by cross linking and mass spectrometry data to investigate the oligomeric state and cell based transport assays to understand mechanism. The manuscript is clearly written and the figures are of good quality and appropriate for the description.

My main concern with the current manuscript is that apart from reporting the structure the study provides little else in the way of insight into the mechanism or regulation of the protein. I felt the manuscript was very descriptive in format but without any significant interpretation. The cross linking analysis appears to have provided little in the way of insight in to the oligomeric state for example. While the authors propose that monomer dimer transitions may occur during regulation of the protein in cells, no evidence is provided that this protein is capable of dimerization. This is rather odd, especially given that the KCC1 structure, which is closely related, was determined as a dimer using a similar technique. I wondered whether the use of 1% DDM might be responsible for disrupting the dimer interaction? I also wondered whether native mass spectrometry might be a better way of analyzing this important aspect of KCC regulation.

Another area of the current study that I found frustrating was the lack of analysis on the role of the extracellular domain. For example, the authors describe the novel extracellular domain, but do not investigate its function, either in cells or in vitro. They describe the glycosylation observed, including what appears to be an interesting link between glycosylation at N312 and TM6A, which forms part of the transport machinery in APC proteins. Yet, the study leaves the reader wondering what the significance of this interaction is. Is it an artifact or an important part of the mechanism? I wondered the same when reading the section that describes the extracellular gate. Here the authors describe a set of salt bridge networks that appear to function similar to LeuT (and other APC transporters), but no analysis is provided. I would have liked to see an attempt made to functionally characterize these interactions, either through transport assays with variants at these sites and charge swapped mutants. Such experiments would greatly illuminate the mechanism of KCC4 and help to put the structure in the context of the function. The same could be said of the bifurcated pathway -- artifact or interesting mechanistic observation. Here mutations and molecular dynamics could shed more insight.

In relation to the comparison between KCC4 and NKCC4, the latter protein binds to Na^+^ in addition to K^+^ and Cl^-^, I was interested to know what compensatory interactions are made that enables KCC4 to dispense with sodium binding. In the APC transporters that move protons for example, the second Na^+^ site is substituted with a lysine. I felt this part of the analysis was also less in depth that warranted.

Overall the manuscript reports the structure of an important membrane protein that will be of interest to a wide range of researchers. However, the study for me was let down by a lack of functional analysis of the protein, starting with the oligomeric state and leading into analysis of the interesting structural features observed. Analysis of the ion binding sites is useful, but ultimately could be seen as fairly obvious and confirmatory, especially given the number of similar APC structures in the literature and the in-depth biochemical analysis conducted on these proteins.

Reviewer \#3:

This manuscript describes the structure of the potassium-chloride cotransporter KCC4 (of *Mus musculus*) in lipid nanodiscs using single particle Cryo-EM. This cotransporter belongs to the CCCs family of which members play important roles in many human physiological functions. Several of these transporters are drug targets because their disruptions are involved in pathological cases. Hence, the KCC4 structure is important both for understanding the structure and function of an important group of mammal\'s transporters as well as for drug design.

1\) KCC4 induced Tl^+^ uptake activity has been demonstrated in intact cells. However, dependence on the symported ion-Cl has only been illustrated. Please, clarify why?

2\) Although, the Tl^+^ uptake due to KCC4 activity was nicely determine in intact cells the structure was determined in nanodiscs. Therefore, there is no indication that the revealed structure is the native functional protein structure. Activity of the protein in nanodiscs is missing and this can be accomplished by testing binding of K^+^/Cl^-^. Using ITC is a simple option.

3\) Structure based mutants support the proposed binding sites and have raised interesting discussion regarding ion/substrate selectivity in this group of transporters. The authors also suggest that amino acid residues residing in the protein\'s extracellular domain form an outward gate of the transporter. This interesting suggestion has to be explored by analyzing mutations at least of the residues that are localized outside the membrane part of the transporter.

10.7554/eLife.52505.sa2

Author response

\[Editors' note: The authors appealed the original decision. What follows is the authors' response to the first round of review.\]

> Our main concerns were as follows:
>
> 1\) While all reviewers find the paper interesting and potentially important, they are concerned that this is the third structure of this family of transporters. The other two, which were published earlier this year, are human KCC1 and DrNKCC1. In your structure, the transmembrane domain is nearly identical to the other two, including the ion binding sites.

While the three CCC structures are similar, there are several major differences with important consequences that we emphasize in this revision with new figures and functional analysis of twenty-one additional mutants (Figures 3A-F, 4C, 5F-H, Figure 2---figure supplement 8, Figure 3---figure supplement 1). First, NKCC1 and KCC1 are dimers (albeit through different interfaces), while KCC4 is a monomer (Figure 3). We show that monomeric KCC4 is active and that its dimerization (through an interface analogous to NKCC1, but not KCC1) increases activity (Figure 3F, more below). Second, substantial rearrangement in the TM region between KCC4 and NKCC1 results in loss of a Na^+^ binding site in KCC4, providing a structural explanation for the difference in substrate specificity and stoichiometry between these transporters (Figure 5C). Third, two Cl^-^ ions are observed in the NKCC1 and KCC1 structures, while one Cl^-^ ion is observed bound to KCC4. Mutations around both sites impair transport activity, suggesting they are both involved in the KCC4 transport cycle (Figure 5F,G). Fourth, the extracellular domains in NKCC1 and KCC1/KCC4 are completely distinct: they are divergent in position within the transporter fold, in sequence, and in structure. Interactions unique to KCCs between the extracellular domain and TM region around the extracellular gate are functionally important (Figure 4C, more below).

> The major difference is that KCC4 is a monomer and the others are dimers. This would be an opportunity to understand dimerization as a new aspect of these transporters. Unfortunately this difference is only addressed superficially in the discussion but without data or analysis. If you can provide evidence that the monomeric form of KCC4 is active, for example by ITC, it would be a valuable addition. If you could show that the ion transport or ion binding kinetics for the monomer and dimer are different, this would add considerable weight to your study.

We performed mutational analysis to assess whether dimerization through either of the distinct interfaces observed in KCC1 and NKCC1 is required for activity in cells (Figure 3). We found that monomeric KCC4 is active and that dimerization through an interface analogous to that observed in NKCC1 increases KCC4 activity (Figure 3F).

KCC1 dimerization predominantly involves protein-detergent interactions between TM regions and protein-protein interactions in an extracellular loop (Figure 3A,B). The extracellular loop is poorly conserved among KCCs (Figure 3E) and in KCC4 its structure is likely incompatible with dimerization due to steric clashes with a second protomer (Figure 3B). Consistently, introduction of three negative charges in the loop in KCC4 has no effect on transport activity. We conclude dimerization as observed in KCC1 is not functionally relevant for KCC4. In contrast, NKCC1 dimerization predominantly involves well conserved protein-protein interactions between CTDs (Figure 3C-E). Three separate pairs of mutations designed to disrupt an analogous interface in KCC4 result in a partial (\~40%) reduction in activity. KCC4 retained activity even when the entire C-terminus was deleted (Figure 3F). Expression and folding were assessed for each mutant in the paper to ensure differences in these factors did not account for activity differences (Figure 3---figure supplement 1). We conclude that monomeric KCC4 is active and that dimerization increases KCC4 activity. This suggests the possibility of regulated dimerization in cells as a means for modulating transport activity in cells. Further exploring this possibility will be a focus of further study.

> 2\) A related concern was that your study provides little in the way of insight into the regulation of the protein. While you propose that monomer-dimer transitions may occur during regulation of the protein in cells, no evidence is provided that this is actually the case.

Based on the structures and mutational studies, we can conclude that monomeric KCC4 is active and that dimerization (in a manner analogous to NKCC1) increases activity (Figure 3F). We believe a study of when this is utilized in cells or in vivo, while certainly very interesting, is outside the realm of this study. We reference a prior report suggesting regulated dimerization of KCC2 occurs in vivo and is associated with an increase in transport activity in conjunction with the neurodevelopmental excitatory-to-inhibitory GABA switch (Blaesse et al., 2006).

> 3\) The fact that KCC4 is a monomer is surprising, given that the KCC1 structure, which is closely related, was determined as a dimer using a similar technique. Could the use of 1% DDM be responsible for disrupting the dimer during isolation? Native mass spectrometry might be a good way of analyzing this important aspect of KCC structure and regulation.

Differences in expression host cells or detergents used in the structures of CCCs do not appear to account for differences in oligomeric state between KCC4 and KCC1 (Figure 3---figure supplement 1). KCC4 and KCC1 displayed similar apparent size (judged by retention time during gel filtration) under all conditions tested (expression in HEK293T or SF9 cells and use of the three detergent combinations used in each CCC structure study (extraction: gel filtration detergents are DDM/CHS:DDM/CHS from KCC4, DDM/CHS:GDN from KCC1, and LMNG/CHS:digitonin from NKCC1).

Since KCC1 and KCC4 behave similarly in these experiments, why is there a difference in oligomeric state in the two structures? One possibility is that KCC1 and KCC4 dimerization interactions are weak and dimeric species are not significantly populated at the low concentrations used for FSEC or, in the case of KCC4, the μM concentrations used for cryo-EM. Regardless, our data suggests an analogous interface is not functionally important for KCC4 as mutation of the extracellular loop that forms the KCC1 dimer interface in a manner predicted to prevent dimerization has no effect on KCC4 function (Figure 3B,F).

In contrast, our data suggests dimerization of KCC4 through the CTDs (as observed in NKCC1) is functionally important and increases KCC4 activity (Figure 3D,F). Consistent with this mode of dimerization in KCCs, structures of KCC2 and KCC3 posted on bioRxiv show an apparently similar CTD-CTD interaction to that observed in NKCC1 (bioRxiv 2020.02.22.960815; doi: https://doi.org/10.1101/2020.02.22.960815). This study also used DDM/CHS and GDN detergents, so detergent differences cannot account for the oligomeric differences between different KCCs observed to date. We speculate differences in KCC oligomeric state and organization could have functional consequences and this will be a focus of future study.

> 4\) A further point that would benefit from additional analysis is the role of the extracellular domain. You describe this domain as novel, but without investigating its function, either in cells or in vitro. You describe glycosylation, including what appears to be an interesting link between glycosylation at N312 and TM6A, which forms part of the transport machinery in APC proteins. Yet, the significance of this interaction is not clear. Is it an artifact or an important part of the mechanism?

We have provided additional mutational analysis of this domain as suggested. Glycosylation at N312 has been observed (at analogous sites) in KCCs in prior reports referenced. We show that glycosylation of N312 is functionally important, consistent with a link between the structure of this region and the extracellular gate around TM6A. KCC4 mutant N312Q results in a severe reduction in transport activity (Figure 4C) without obvious defects in folding or expression.

> 5\) We also wondered about the extracellular gate, where you describe a salt bridge network that may function in a similar way to LeuT (and other APC transporters), but no analysis is provided. It would be good to characterize these interactions, for example through transport assays with variants at these sites and charge-swapped mutants. Such experiments would illuminate the mechanism of KCC4 and help to put the structure into a functional context.

We have added mutational analysis of the proposed gate between the TM region and extracellular domain (Figure 4C). Consistent with the importance of the hydrophobic and electrostatic interaction network we describe, mutation of key residues involved (K485D, K485E, F486A, and R140E) significantly reduce transport activity.

> Reviewer \#1:
>
> This paper describes the cryo-EM structure of KCC4, a K^+^/Cl^-^ cotransporter from *Mus musculus*. The structural work is well done, two residues in the ion-binding sites were mutated to demonstrate their importance to transport activity.
>
> My main concern is this:
>
> This is the third structure of this family of transporters. The other two, which were published earlier this year, are human KCC1 and DrNKCC1. The new structure in detail is nearly identical to the previous ones, including the ion binding sites. Some of the figures here are also similar.

Please see main concern \#1 above. Some figures were purposefully made similar to facilitate simple comparisons with the NKCC1 paper.

> The major difference is that KCC4 is a monomer and the others are dimers. This is an opportunity to understand an aspect of these transporters that until now was unknown. Unfortunately this difference is only addressed superficially in discussion but not with data and analysis. If the authors can provide evidence that the monomeric form of KCC4 is functional, then this work will make a good contribution towards our understanding of the architecture and function of KCCs.

Please see main concern \#1-3. We provide evidence of functional monomeric KCC4 and that dimerization as observed in NKCC1 appears to increase activity, consistent with a proposed role for regulated oligomerization modulating transport activity.

> Reviewer \#2:
>
> \[...\]
>
> My main concern with the current manuscript is that apart from reporting the structure the study provides little else in the way of insight into the mechanism or regulation of the protein. I felt the manuscript was very descriptive in format but without any significant interpretation. The cross linking analysis appears to have provided little in the way of insight in to the oligomeric state for example. While the authors propose that monomer dimer transitions may occur during regulation of the protein in cells, no evidence is provided that this protein is capable of dimerization. This is rather odd, especially given that the KCC1 structure, which is closely related, was determined as a dimer using a similar technique. I wondered whether the use of 1% DDM might be responsible for disrupting the dimer interaction? I also wondered whether native mass spectrometry might be a better way of analyzing this important aspect of KCC regulation.

Please see Main concern \#1-3 above. We provide evidence that dimerization as observed in KCC1 is irrelevant for KCC4 function, for functional monomeric KCC4, and for dimerization as observed in NKCC1 increasing transport activity. We agree understanding when in cells regulated oligomerization could occur is an interesting and important next step, but would prefer to explore this broad question in future work.

> Another area of the current study that I found frustrating was the lack of analysis on the role of the extracellular domain. For example, the authors describe the novel extracellular domain, but do not investigate its function, either in cells or in vitro. They describe the glycosylation observed, including what appears to be an interesting link between glycosylation at N312 and TM6A, which forms part of the transport machinery in APC proteins. Yet, the study leaves the reader wondering what the significance of this interaction is. Is it an artifact or an important part of the mechanism? I wondered the same when reading the section that describes the extracellular gate. Here the authors describe a set of salt bridge networks that appear to function similar to LeuT (and other APC transporters), but no analysis is provided. I would have liked to see an attempt made to functionally characterize these interactions, either through transport assays with variants at these sites and charge swapped mutants. Such experiments would greatly illuminate the mechanism of KCC4 and help to put the structure in the context of the function. The same could be said of the bifurcated pathway -- artifact or interesting mechanistic observation. Here mutations and molecular dynamics could shed more insight.

Please see main concern \#4 and \#5. We provide evidence that both glycosylation and the electrostatic and hydrophobic interaction network that structurally couples the extracellular domain to the TM region and the outer gate are functionally important.

> In relation to the comparison between KCC4 and NKCC4, the latter protein binds to Na^+^ in addition to K^+^ and Cl^-^, I was interested to know what compensatory interactions are made that enables KCC4 to dispense with sodium binding. In the APC transporters that move protons for example, the second Na^+^ site is substituted with a lysine. I felt this part of the analysis was also less in depth that warranted.

The differences are shown in Figure 5C and detailed in the text. Rather than introduction of a compensatory charged residue like lysine, loss of the Na^+^ site involves large scale helical shifts and mutation of coordinating residues to more broadly change the chemical nature of the Na^+^ site.

> Reviewer \#3:
>
> \[...\]
>
> 1\) KCC4 induced Tl^+^ uptake activity has been demonstrated in intact cells. However, dependence on the symported ion-Cl has only been illustrated. Please, clarify why?

One reason is that only a narrow range of \[Cl^-^\]~ext~ is accessible using the Tl^+^ assay due to the very low solubility of TlCl salt that interferes with the assay. We agree this will be an interesting avenue to explore in future work with a different assay.

> 2\) Although, the Tl^+^ uptake due to KCC4 activity was nicely determine in intact cells the structure was determined in nanodiscs. Therefore, there is no indication that the revealed structure is the native functional protein structure. Activity of the protein in nanodiscs is missing and this can be accomplished by testing binding of K^+^/Cl^-^. Using ITC is a simple option.

We believe a thermodynamic characterization of ion binding, while certainly interesting, is best suited for future work. We think the structure observed is functionally relevant for the following reasons. First, we observe ions bound in the structure and mutations at these sites disrupt transport. Second, residues predicted from the structure to form part of a previously unseen extracellular gate interaction and a unique connection between a glycosylation site and the gate were shown to be functionally important. Third, our mutational data at putative dimerization sites is consistent with functional monomeric KCC4. Fourth, five distinct CCCs have now been structurally captured in an overall similar conformation.

> 3\) Structure based mutants support the proposed binding sites and have raised interesting discussion regarding ion/substrate selectivity in this group of transporters. The authors also suggest that amino acid residues residing in the protein\'s extracellular domain form an outward gate of the transporter. This interesting suggestion has to be explored by analyzing mutations at least of the residues that are localized outside the membrane part of the transporter.

Please see main concern \#4 and 5.
